MassMutual Private Wealth & Trust FSB Has $39.20 Million Stock Position in AbbVie Inc. $ABBV

Key Points

• MassMutual Private Wealth & Trust FSB trimmed its position in AbbVie by 3.4% in Q4 to 171,575 shares valued at $39.20 million, representing 1.0% of the firm's portfolio and its 23rd-largest holding.
• AbbVie topped Q4 estimates with $2.71 EPS and $16.62 billion in revenue (up 10% YoY) and set FY2026 EPS guidance of 14.370–14.570 and Q1 guidance of 2.970–3.010.
• AbbVie pays a $1.73 quarterly dividend (annualized $6.92, ~3.4% yield) despite a high payout ratio (293%), and faces near-term pressure from competitors (J&J’s oral IL‑23 approval and a generic Savella), while analysts hold a consensus Moderate Buy rating with an average target of $253.15.

MassMutual Private Wealth & Trust FSB lessened its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 171,575 shares of the company's stock after selling 5,981 shares during the quarter. AbbVie comprises 1.0% of MassMutual Private Wealth & Trust FSB's investment portfolio, making the stock its 23rd biggest position. MassMutual Private Wealth & Trust FSB's holdings in AbbVie were worth $39,203,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Evolution Wealth Management Inc. bought a new position in AbbVie in the 2nd quarter valued at about $26,000. Chelsea Counsel Co. bought a new stake in shares of AbbVie during the 3rd quarter worth approximately $26,000. Texas Capital Bancshares Inc TX acquired a new stake in shares of AbbVie during the 3rd quarter worth approximately $31,000. Caitlin John LLC acquired a new stake in shares of AbbVie during the 3rd quarter worth approximately $33,000. Finally, Delos Wealth Advisors LLC bought a new position in AbbVie in the second quarter valued at approximately $39,000. Institutional investors own 70.23% of the company's stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $204.34 on Friday. The company's 50 day moving average price is $223.09 and its two-hundred day moving average price is $224.76. The firm has a market capitalization of $361.31 billion, a P/E ratio of 86.59, a P/E/G ratio of 0.71 and a beta of 0.34. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the business earned $2.16 earnings per share. The company's revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.4%. AbbVie's dividend payout ratio (DPR) is currently 293.22%.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by company insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie signed a multi‑year collaboration with Alloy Therapeutics to develop a next‑generation antibody discovery platform aimed at hard‑to‑drug immunology targets — a pipeline boost that could support future biologics and reduce reliance on existing blockbusters. Is AbbVie (ABBV) Quietly Rewiring Its Immunology Edge With Alloy’s Antibody Discovery Deal?
• Positive Sentiment: Allergan Aesthetics (an AbbVie company) released global consumer research and is rolling out updated educational and treatment frameworks, reinforcing revenue diversification in aesthetic products and services. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: The U.S. FDA asked manufacturers of certain Parkinson’s drugs to add seizure‑risk warnings — a classwide safety advisory that may affect companies with Parkinson’s portfolios; AbbVie’s direct exposure is unclear but investors should monitor any label updates. US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
• Neutral Sentiment: Macro/flow note — commentary about defensive ETFs and rotation into dividend/defensive sectors could support demand for large dividend payers like AbbVie, but it’s not a catalyst unique to the company. The Market’s Favorite Active ETF Was Made for This Moment. Is It Delivering?
• Negative Sentiment: Johnson & Johnson’s FDA approval of Icotyde, a once‑daily oral IL‑23 inhibitor, materially raised competitive concerns for AbbVie’s Skyrizi (an injectable IL‑23 product). The market reacted sharply as an oral pill can take share from injectables, driving recent ABBV weakness. ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?
• Negative Sentiment: A generic entrant (Milnacipran HCl) for Savella® was launched, signaling ongoing generic pressure on some of AbbVie’s older products and modest revenue risk in pain management categories. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®
• Negative Sentiment: Short‑term price action: analysts and market pieces highlight a recent pullback and underperformance vs. peers, amplifying volatility as investors re‑price growth assumptions for Skyrizi and the company’s near‑term outlook. AbbVie (ABBV) Declines More Than Market: Some Information for Investors

Analysts Set New Price Targets

Several research analysts have commented on ABBV shares. William Blair restated an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $223.00 price target on shares of AbbVie in a research note on Wednesday, January 28th. Sanford C. Bernstein reissued a "market perform" rating on shares of AbbVie in a report on Thursday, February 5th. Citigroup dropped their price objective on AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research report on Tuesday, January 27th. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.